Oppenheimer Considers Merck & Co. (MRK) Agreement as Strong Endorsement for Veeva's Vault CRM

Merck & Co., Inc. (NYSE:MRK) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, Oppenheimer analyst Ken Wong noted that Outperform-rated Veeva announced that Merck & Co., Inc. (NYSE:MRK) has committed to Vault CRM. The announcement marks Veeva’s sixth enterprise pharma Vault CRM commitment.

The firm stated that the company is gaining momentum leading up to the September GA of Salesforce’s Life Sciences Cloud for Customer Engagement.

It also considers the announcement to be incrementally positive, but also stated that the commitment to Merck was broadly expected because of the long-term strategic partnership between the two companies.

Oppenheimer added that Merck is the largest pharma company in the world by revenue, and a strong endorsement for Vault CRM.

Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people.

Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.